MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3324/haematol.2026.300775

Медицинская библиотека · Haematologica · 2026

Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia and therapy-related myeloid neoplasms.

Baccelli Francesco, Merli Pietro, Pigazzi Martina, Buldini Barbara, Becilli Marco, Girardi Katia, Paganelli Valeria, Pagano Gennaro, Leardini Davide, Muratore Edoardo, Vendemini Francesca, Beneduce Giuliana, Tumino Manuela, Saglio Francesco, Sieni Elena, Mastrodicasa Elena, Maffeis Marianna, Tambaro Francesco Paolo, Masetti Riccardo, Locatelli Franco

СтатьяПеревод в очереди

Аннотация

Pediatric refractory/relapsed acute myeloid leukemia (r/r-AML), myelodysplastic syndromes with excess blasts (MDSEB), and therapy-related MDS/AML (t-MDS/AML) remain a clinical challenge due to high rate of treatment failure. Venetoclax plus azacytidine (ven/aza) has transformed adult myeloid neoplasm treatment, but pediatric data are limited and heterogeneous. This AIEOP retrospective, multicenter study analyzed 50 patients (M/F=1.8/1; median age 11 years) with r/r-AML (n=32), MDS-EB (n=10), or t-MDS/AML (n=8) treated with ven/aza. Responses were defined as complete (CR), partial (PR), or non-response (NR) based on bone marrow (BM) blast evaluation. Adverse events (AEs) were graded per CTCAE v5.0; outcomes were evaluated with Kaplan-Meier and Cox-regression analysis. Patients received a median of 2 cycles (range, 1-7). Grade ≥3 AEs occurred in 34% of patients. Overall, 30 patients (60%) achieved CR (24 MRD-negative), 9 (18%) PR, and 11 (22%) NR. CR were 58%, 57% and 100% in KMT2A-AML, FLT3-ITD-AML (ven/aza+FLT3-inhibitors) and UBTF-TD myeloid neoplasms, respectively. In 10 MDS-EB, 7 CR and 2 PR were recorded. In 8 t-MDS/AML, we observed 5 CR and 2 PR. Thirty-three patients (66%) underwent hematopoietic cell transplantation (HCT), after a median of 97 days (range: 33-933) from ven/aza start. Median follow-up was 389 days (range 36-1405). Two-year event-free survival (EFS) was 54.5% (CI:46.7-62.3), being 75.8% in transplanted patients, and 77.2% in those achieving CR. CR and HCT were associated with better EFS. Ven/aza shows substantial activity and manageable toxicity in pediatric high-risk myeloid diseases, especially as a bridge to HCT and in specific molecular subgroups, supporting future, prospective, genetically-guided studies.

Для цитирования: Baccelli Francesco, Merli Pietro, Pigazzi Martina, Buldini Barbara, Becilli Marco, Girardi Katia, Paganelli Valeria, Pagano Gennaro, Leardini Davide, Muratore Edoardo, Vendemini Francesca, Beneduce Giuliana, Tumino Manuela, Saglio Francesco, Sieni Elena, Mastrodicasa Elena, Maffeis Marianna, Tambaro Francesco Paolo, Masetti Riccardo, Locatelli Franco. Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia and therapy-related myeloid neoplasms.. Haematologica. 2026. DOI: 10.3324/haematol.2026.300775.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.